AML

Schrödinger Provides Update on Progress Across the Business and Outlines 2024 Development and Operational Goals

Retrieved on: 
Monday, January 8, 2024
Health, Technology, Software, Research, Science, Pharmaceutical, Biotechnology, PKA, Lilly, Drug discovery, Lymphoid leukemia, ADMET, IND, CDC7, MDS, Eli Lilly and Company, MBBS, NLRP3, MALT1, Webcast, Patient, Therapy, AML, Pharmaceutical industry

Schrödinger , Inc. (Nasdaq: SDGR), Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today provided an update on its progress across the business and announced its development and operational goals for 2024.

Key Points: 
  • Schrödinger , Inc. (Nasdaq: SDGR), Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today provided an update on its progress across the business and announced its development and operational goals for 2024.
  • Today Schrödinger announced an expanded, three-year, software agreement with Eli Lilly and Company.
  • The three-year agreement builds on the collaboration established in 2022.
  • Schrödinger will provide advanced support to ensure full integration and optimization of the platform across Lilly’s research sites.

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024

Retrieved on: 
Monday, January 8, 2024
Autoimmune disease, Completeness, Ovarian cancer, PROC, AZA, TP53, Anemia, Society, Clinical trial, Cancer, Event, Azacitidine, Investment, Webcast, Patient, Safety, PLD, Acceleration, AML, Mirvetuximab soravtansine, Pharmaceutical industry

AUSTIN, TX and DURHAM, NC, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today provided a corporate update and highlighted upcoming key milestones anticipated in 2024.

Key Points: 
  • AUSTIN, TX and DURHAM, NC, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today provided a corporate update and highlighted upcoming key milestones anticipated in 2024.
  • “In 2023, we delivered key safety and efficacy data across our clinical development program for SL-172154 and further strengthened our financial resources, which we believe will carry us beyond upcoming milestones in the year ahead,” said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck Labs.
  • On December 21, 2023, Shattuck announced a $50 million registered offering of common stock and concurrent private placement of pre-funded warrants.
  • Initial combination data from the Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in PROC expected mid-year 2024.

Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024

Retrieved on: 
Monday, January 8, 2024
LDAC, Medicine, IND, Colorectal cancer, EGFR, BRG1, Prostate cancer, Factorization of polynomials, MDS, Thrombocytopenia, Gene expression, Chromatin, Neoplasm, Prostate, CBP, Cancer, Patient, Safety, ARID1B, AML, NSCLC, BRM, EP300, Pharmaceutical industry

This will also include preclinical combination data of FHD-286 with tyrosine kinase inhibitors of EGFR and KRAS.

Key Points: 
  • This will also include preclinical combination data of FHD-286 with tyrosine kinase inhibitors of EGFR and KRAS.
  • Over the next four years, we anticipate the filing of at least six new INDs, reflecting the productivity of our precision medicine platform.
  • This is all supported by our cash and equivalents position of approximately $259.9 million as of September 30, 2023.”
    FHD-286.
  • Foghorn is engaged in a strategic collaboration with Loxo@Lilly and continues to advance the BRM selective inhibitor and degrader programs along with other undisclosed programs.

Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene

Retrieved on: 
Monday, January 8, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, RARA, Aplastic anemia, Bone marrow, New Drug Application, Syros, Azacitidine, Venetoclax, Patient, Acute myeloid leukemia, AML, Pharmaceutical industry

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today highlighted anticipated 2024 milestones to deliver on the value of tamibarotene.

Key Points: 
  • Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today highlighted anticipated 2024 milestones to deliver on the value of tamibarotene.
  • In addition, we closed an approximately $45.0 million equity financing, providing us additional capital to advance the development of tamibarotene.
  • By the middle of the fourth quarter of 2024, we expect to report pivotal data from the SELECT-MDS-1 Phase 3 clinical trial.
  • Syros is also evaluating tamibarotene in combination with venetoclax and azacitidine in newly diagnosed unfit AML patients with RARA overexpression.

Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Sunday, January 7, 2024
NAMD, Conference, Gene family, Partnership, Neoplasm, Tumor microenvironment, IND, Hematopoietic stem cell transplantation, Radionuclide, CD47, Data, Myelodysplastic syndrome, Macrophage, Molecular Partners, HSC, Society, CHF, Novartis, ASH, COVID-19, DARPin, Toxicity, RDT, CD16, Stem cell, HSCT, Patient, Acute myeloid leukemia, Safety, Therapy, AML, DLL3, Health, SITC, Pharmaceutical industry

53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced it will present a business overview and provide its 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced it will present a business overview and provide its 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference.
  • Data were presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2023.
  • Molecular Partners continues to progress its RDT platform and portfolio of projects, both in-house and in partnership with Novartis.
  • In addition to these updates, Novartis has returned the rights to the ensovibep program, previously under investigation for the treatment of COVID-19, to Molecular Partners.

Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024

Retrieved on: 
Sunday, January 7, 2024
Gene editing, FDA, Orphan drug, Troy University, Lymphoma, Multiple myeloma, Conference, Mechanics, Amplification, University, Rachel Haurwitz, Air force academy, ASCT, Regenerative Medicine Advanced Therapy, Food, CRISPR, UCB, AAV, Engineering, Patient, Medicine, Fast Track, Westmead Hospital, MD, Doctor of Philosophy, Reindeer, Infrared spectroscopy correlation table, United States Air Force, PST, Organization, AML, Pharmaceutical industry

-- Caribou to present at 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, at 11:15 am PST --

Key Points: 
  • In addition, Caribou highlighted successful execution across its allogeneic CAR-T cell therapy platform over the past year and provided an outlook on multiple clinical catalysts planned for 2024.
  • We are excited to kick off 2024 by welcoming Tim Kelly as Caribou’s chief technology officer,” said Rachel Haurwitz, PhD, Caribou’s president and chief executive officer.
  • Appointed Tim Kelly as Caribou’s chief technology officer, leading the company’s process development and manufacturing organizations.
  • CB-012: Caribou plans to initiate patient enrollment in the AMpLify Phase 1 clinical trial in r/r AML in H1 2024.

Human medicines European public assessment report (EPAR): Azacitidine Accord, azacitidine, Date of authorisation: 13/02/2020, Revision: 7, Status: Authorised

Retrieved on: 
Saturday, January 6, 2024
Patient, RNA, Medical Subject Headings, Liver, Marketing, INN, Risk, Classification, Bone marrow, ATC, IPSS, International, WHO, B cell, Myeloid tissue, Azacitidine, Myelodysplastic syndrome, CMML, DNA, Nausea, Blood, Language, MDS, Cancer, Abdomen, Death, Myelocyte, European Medicines Agency, Syndrome, Monocyte, Thigh, Growth, Select, HSCT, Anatomy, AML, Pancreatic serous cystadenoma, Acute leukemia, IIA, Skin, Cytidine, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Azacitidine Accord, azacitidine, Date of authorisation: 13/02/2020, Revision: 7, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Azacitidine Accord, azacitidine, Date of authorisation: 13/02/2020, Revision: 7, Status: Authorised

Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program

Retrieved on: 
Friday, January 5, 2024
Workforce, Gene, SNTI, Partnership, Food, Hepatocellular carcinoma, IND, Doctor of Philosophy, Therapy, Investigational New Drug, Bone marrow, Acute myeloid leukemia, Patient, AML, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced plans to streamline its business operations, including reducing its workforce by approximately 37 percent, to enable increased focus on SENTI-202, a first-in-class Logic Gated investigational cell therapy for the treatment of acute myeloid leukemia (“AML”). The Investigational New Drug (“IND”) application for SENTI-202 was cleared by the U.S. Food and Drug Administration (“FDA”) in December 2023 and the Company anticipates dosing the first patient in the second quarter of 2024. Additionally, the Company will continue to support the clinical development activities of SENTI-301A for the treatment of advanced glypican 3 (“GPC3”)-expressing hepatocellular carcinoma (“HCC”) in China through its partnership with Celest Therapeutics. The Company expects that these resource allocation efforts, combined with other expected receivables, will extend its cash runway into the first quarter of 2025.

Key Points: 
  • Additionally, the Company will continue to support the clinical development activities of SENTI-301A for the treatment of advanced glypican 3 (“GPC3”)-expressing hepatocellular carcinoma (“HCC”) in China through its partnership with Celest Therapeutics.
  • The Company expects that these resource allocation efforts, combined with other expected receivables, will extend its cash runway into the first quarter of 2025.
  • Despite this progress, we are taking the difficult but necessary steps to enhance our focus on demonstrating clinical proof-of-concept for our Gene Circuit technology and potentially bringing SENTI-202 and SENTI-301A to patients,” said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio.
  • “With these resource allocation efforts, our team will remain laser-focused on the clinical progress of SENTI-202 and supporting our partnership with Celest Therapeutics for SENTI-301A in China.

Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones

Retrieved on: 
Friday, January 5, 2024
Omalizumab, Subcutaneous, CD117, Risk, IND, EMA, FA, Chairperson, Cold urticaria, Therapy, MDS, Chronic, Fanconi anemia, ASH, Annual general meeting, European Medicines Agency, Syndrome, CSU, SVP, Patient, Acute myeloid leukemia, Safety, AML, CTA, Pharmaceutical industry

REDWOOD CITY, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced its recent accomplishments, including the authorization by the European Medicines Agency (EMA) of the Company’s Clinical Trial Applications (CTA) for its Phase 1b/2a trials of briquilimab in CIndU and CSU, and outlined its corporate priorities and anticipated milestones for 2024. Called SPOTLIGHT – “Study (Phase 1b/2a) Of subcuTaneous brIquilimab in patients diaGnosed with cHronic inducible urTicaria” – the CIndU study will evaluate single doses of subcutaneous briquilimab in adult patients with cold urticaria or symptomatic dermographism.

Key Points: 
  • “2023 was a strategically important year for Jasper,” said Ronald Martell, President and Chief Executive Officer of Jasper.
  • “We secured IND clearance and CTA authorization for the Phase 1b/2a BEACON study of briquilimab in CSU and successfully dosed the first patient.
  • Our achievements in 2023 set the stage for a transformational year ahead with multiple key clinical milestones on the horizon across multiple indications.
  • Strengthened the organization with key leadership appointments including Thomas Wiggans as Chairperson of the Board of Directors, Scott Brun, M.D.

Global Anti-Money Laundering (AML) Market Report 2023-2028: Analysis of KYC/CDD & Sanctions Screening, Transaction Monitoring, Case Management & Reporting, and Services - ResearchAndMarkets.com

Retrieved on: 
Friday, January 5, 2024
Professional Services, Finance, SAS Institute, Business transaction management, Software, Bank, GB Group, Region, Internet, AI, NICE Ltd., LexisNexis, Case management, Growth, Investment, Organization, AML, Algorithm, FIS, ACI Worldwide, FICO, Cryptocurrency

In the early stages, AML efforts primarily relied on rule-based systems that flagged transactions based on predetermined thresholds and patterns.

Key Points: 
  • In the early stages, AML efforts primarily relied on rule-based systems that flagged transactions based on predetermined thresholds and patterns.
  • However, these systems often generated high volumes of false positives, overwhelming compliance teams and leading to inefficient use of resources.
  • North America is estimated to be the largest contributor in terms of the market size in the AML market.
  • The study includes an in-depth competitive analysis of the key players in the AML market, their company profiles, recent developments, and key market strategies.